Table 3 Prevalence of resistant P. aeruginosa isolates in different hospitals.

From: Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates

Antibiotics

Hospitals

Total

p-value*

Namazi

Rajaee

Amir

CAZ

20 (80%)

3 (12%)

2 (8%)

25 (35.7%)

0.015

CTX

24 (77.4%)

5 (16.1%)

2 (6.5%)

31 (44.2%)

0.011

PIP

17 (81%)

2 (9.5%)

2 (9.5%)

21 (30%)

0.066

PTZ

16 (76.2%)

3 (14.3)

2 (9.5%)

21 (30%)

0.083

AZT

15 (78.9%)

1 (5.3%)

3 (15.8%)

19 (27.1%)

0.001

MRO

16 (72.7%)

2 (9.1%)

4 (18.2%)

22 (31.4%)

0.083

IMP

20 (76.9%)

2 (7.7%)

4 (14.4%)

26 (37.1%)

0.008

CIP

16 (69.6%)

3 (13%)

4 (17.4%)

23 (32.9%)

0.272

GEN

17 (7.8%)

4 (16.7%)

3 (12.5%)

24 (34.3%)

0.076

TOB

20 (71.4%)

4 (14.3%)

4 (14.3%)

28 (40%)

0.031

AMK

15 (71.4%)

3 (14.3%)

3 (14.3%)

21 (30%)

0.085

COL

25 (48.1%)

18 (34.6%)

9 (17.3%)

52 (74.3%)

0.007

MDR

18 (69.2%)

4 (15.4%)

4 (15.4%)

26 (32.9%)

0.117

CRPA

18 (36.8%)

4 (20%)

4 (33.3%)

25 (35.7%)

0.004

  1. CAZ: ceftazidime, CTX: cefotaxime, PIP: piperacillin, PTZ: piperacillin/tazobactam, AZT: aztreonam, MRO: meropenem, IMP: imipenem, CIP: ciprofloxacin, GEN: gentamicin, TOB: tobramycin, AMK: amikacin, COL: colistin, MDR: multi-drug resistant.
  2. *p value ≤ 0.05 is significant.
Back to article page